141 related articles for article (PubMed ID: 28178680)
1. Prognostic value of follistatin-like 3 in human invasive breast cancer.
Couto HL; Buzelin MA; Toppa NH; Bloise E; Wainstein AJ; Reis FM
Oncotarget; 2017 Jun; 8(26):42189-42197. PubMed ID: 28178680
[TBL] [Abstract][Full Text] [Related]
2. Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer.
Yang C; Cao F; Huang S; Zheng Y
Front Immunol; 2021; 12():717505. PubMed ID: 34335633
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice.
Xia Y; Sidis Y; Schneyer A
Mol Endocrinol; 2004 Apr; 18(4):979-94. PubMed ID: 14739256
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of follistatin and FLRG in human breast proliferative disorders.
Bloise E; Couto HL; Massai L; Ciarmela P; Mencarelli M; Borges LE; Muscettola M; Grasso G; Amaral VF; Cassali GD; Petraglia F; Reis FM
BMC Cancer; 2009 Sep; 9():320. PubMed ID: 19740438
[TBL] [Abstract][Full Text] [Related]
5. Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3.
Saito S; Sidis Y; Mukherjee A; Xia Y; Schneyer A
Endocrinology; 2005 Dec; 146(12):5052-62. PubMed ID: 16150905
[TBL] [Abstract][Full Text] [Related]
6. The cytoplasmic expression of FSTL3 correlates with colorectal cancer progression, metastasis status and prognosis.
Li CH; Fang CY; Chan MH; Chen CL; Chang YC; Hsiao M
J Cell Mol Med; 2023 Mar; 27(5):672-686. PubMed ID: 36807490
[TBL] [Abstract][Full Text] [Related]
7. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
Sidis Y; Mukherjee A; Keutmann H; Delbaere A; Sadatsuki M; Schneyer A
Endocrinology; 2006 Jul; 147(7):3586-97. PubMed ID: 16627583
[TBL] [Abstract][Full Text] [Related]
8. Follistatin Expression in Human Invasive Breast Tumors: Pathologic and Clinical Associations.
Couto HL; Dela Cruz C; Buzelin MA; Toppa NH; Wainstein AJ; Reis FM
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):108-112. PubMed ID: 27389553
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
[TBL] [Abstract][Full Text] [Related]
10. Regulation of follistatin-like 3 expression by miR-486-5p modulates gastric cancer cell proliferation, migration and tumor progression.
Dai ZT; Xiang Y; Zhang XY; Zong QB; Wu QF; Huang Y; Shen C; Li JP; Ponnambalam S; Liao XH
Aging (Albany NY); 2021 Aug; 13(16):20302-20318. PubMed ID: 34425560
[TBL] [Abstract][Full Text] [Related]
11. Heparin and activin-binding determinants in follistatin and FSTL3.
Sidis Y; Schneyer AL; Keutmann HT
Endocrinology; 2005 Jan; 146(1):130-6. PubMed ID: 15471966
[TBL] [Abstract][Full Text] [Related]
12. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
14. Differential actions of follistatin and follistatin-like 3.
Schneyer A; Sidis Y; Xia Y; Saito S; del Re E; Lin HY; Keutmann H
Mol Cell Endocrinol; 2004 Oct; 225(1-2):25-8. PubMed ID: 15451564
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
17. The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study.
Jaillardon L; Abadie J; Godard T; Campone M; Loussouarn D; Siliart B; Nguyen F
BMC Cancer; 2015 Oct; 15():664. PubMed ID: 26449867
[TBL] [Abstract][Full Text] [Related]
18. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.
Seachrist DD; Sizemore ST; Johnson E; Abdul-Karim FW; Weber Bonk KL; Keri RA
Breast Cancer Res; 2017 Jun; 19(1):66. PubMed ID: 28583174
[TBL] [Abstract][Full Text] [Related]
19. Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinoma.
Ciarmela P; Florio P; Sigurdardottir M; Toti P; Maguer-Satta V; Rimokh R; Altomare A; Tosi P; Petraglia F
Eur J Endocrinol; 2004 Aug; 151(2):251-7. PubMed ID: 15296481
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
